Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492605 | 0.86 | CNR1 (0.36) | ALDH1A1POLBMEN1KMT2AHPGD | |
| SCHEMBL6479708 | 0.85 | ROCK1 (0.34) | ALDH1A1MEN1KMT2AHPGDRAB9A | |
| SCHEMBL6492314 | 0.77 | EGLN1 (0.59) | ALDH1A1EGLN1HDAC6LMNA | |
| SCHEMBL6480924 | 0.70 | MAPT (0.48) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL6480537 | 0.67 | FEN1 (0.60) | ALDH1A1EGLN1HDAC6KDRLMNA | |
| SCHEMBL6480271 | 0.67 | EGLN1 (0.43) | ALDH1A1EGLN1HPGD | |
| SCHEMBL10707617 | 0.67 | MAPT (0.57) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL4256922 | 0.67 | HDAC3 (0.46) | ALDH1A1HDAC6MEN1KMT2AHDAC4 | |
| SCHEMBL12472139 | 0.66 | EGLN1 (0.61) | ALDH1A1EGLN1POLBHDAC6MEN1 | |
| SCHEMBL6478551 | 0.65 | CCR1 (0.39) | ALDH1A1EGLN1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | ZHUANG LINGHANG (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010048-A1 | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors | POLI, CYP51A1, DUT | ALDH1A1 1974/4885EGLN1 2187/4885POLB 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.